A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis
1 other identifier
interventional
180
13 countries
84
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jul 2024
Typical duration for phase_3
84 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2024
CompletedFirst Posted
Study publicly available on registry
June 13, 2024
CompletedStudy Start
First participant enrolled
July 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
March 10, 2026
March 1, 2026
2.8 years
June 7, 2024
March 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24
The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale is scored on a 0 to 3 (0=normal, 3=severe disease) point scale. The total score is the sum of all individual item scores ranging from 0 to 24. Higher scores indicate more severe disability due to MG. A decrease from Baseline score indicates improvement.
Week 24
Secondary Outcomes (5)
Change from baseline in Quantitative Myasthenia Gravis (QMG) score at Week 24
Week 24
Change from baseline in MG Quality of Life scale (MG-QOL15r) at Week 24
Week 24
Proportion of patients with a decrease of ≥2 points from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24
Week 24
Proportion of patients with a decrease of ≥3 points from baseline in Quantitative Myasthenia Gravis (QMG) score at Week 24
Week 24
Proportion of patients who achieved minimal symptomatic expression (MSE, defined as having MG-ADL score of 0 or 1) at Week 24
Week 24
Study Arms (2)
Telitacicept
EXPERIMENTALTelitacicept
Placebo
PLACEBO COMPARATORPlacebo
Interventions
Eligibility Criteria
You may qualify if:
- Male or female patient aged ≥18 years at screening.
- Patients have prior confirmed diagnosis of gMG with generalized muscle weakness (typical pattern of weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) clinical classification II-IV.
- Patients have positive antibodies against AChR or MuSK at screening.
- MG-ADL score ≥6 points at screening and baseline with ocular-related score \<50% of the total score.
- QMG score ≥8 points, and ≥ 4 items score at least 2 points at screening and baseline.
You may not qualify if:
- Patients have been diagnosed with any other autoimmune disease which can potentially pose a safety or efficacy confounding risk.
- Patients having acute or chronic infection.
- Patients having thymoma within 5 years or received thymectomy ≤6 months prior to screening. Patients with thymoma diagnosed 3-5 years prior to screening may be eligible if thymoma was at a localized stage and definitively treated with complete surgical resection.
- Patients having current or history of primary immunodeficiency.
- Patients having history of malignancy within the last 5 years.
- Patient having prior or continuing diagnosis of serious cardiovascular, liver, kidney, respiratory system, endocrine or hematologic disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Vor Biopharmalead
Study Sites (84)
University of Southern California
Los Angeles, California, 90033, United States
University of California Irvine
Orange, California, 92868, United States
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
SFM Clinical Research
Boca Raton, Florida, 33487, United States
Allied Biomedical Research Institute (ABRI)
Miami, Florida, 33155, United States
Medsol Clinical Research Center
Port Charlotte, Florida, 33952, United States
Wellstar MCG Health Medical Center
Augusta, Georgia, 30912, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
University of Kentucky
Lexington, Kentucky, 40506, United States
University of Louisville Physicians
Louisville, Kentucky, 40202, United States
Neurology Center of New England
Foxborough, Massachusetts, 02035, United States
Michigan State University Clinical Center
East Lansing, Michigan, 48824, United States
Trinity Health - Grand Rapids Hospital
Grand Rapids, Michigan, 49503, United States
Mount Sinai Health System
New York, New York, 10029, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
University of Cincinnati Health Physicians - Clifton
Cincinnati, Ohio, 45219, United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Houston Methodist Neurological Institute
Houston, Texas, 77030, United States
Center for Neurological Disorders, S.C. - Greenfield - Gamma Therapeutic Center
Greenfield, Wisconsin, 53228, United States
STAT Research S.A.
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1023AAB, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina
Hospital General de Agudos José María Ramos Mejía
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1221ADC, Argentina
INECO Neurociencias Oroño
Rosario, Santa Fe Province, S2000TP, Argentina
Fundación Scherbovsky
Mendoza, M5500AXR, Argentina
Concord Repatriation General Hospital
Concord, New South Wales, 2139, Australia
Townsville University Hospital
Douglas, Queensland, 4814, Australia
Gold Coast University Hospital
Southport, Queensland, 4215, Australia
Universitair Ziekenhuis (UZ) Leuven - Campus Gasthuisberg
Leuven, Flemish Brabant, 3000, Belgium
Instituto de Neurologia de Curitiba
Curitiba, Paraná, 81210-310, Brazil
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, 90619-900, Brazil
Universidade Estadual de Campinas
Campinas, São Paulo, 13083-888, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
Ribeirão Preto, São Paulo, 14051-140, Brazil
Pseg Centro de Pesquisa Clinica
São Paulo, 04038-002, Brazil
University Hospital - London Health Sciences Centre
London, Ontario, N6C 2R5, Canada
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
Fakultni Nemocnice Ostrava
Ostrava-Poruba, Moravian-Silesian, 708 54, Czechia
MINKSneuro s.r.o. - MUDr. Eduard Minks Ph.D.
Brno, South Moravian, 603 00, Czechia
Fakultni Nemocnice Brno
Brno, South Moravian, 625 00, Czechia
Hôpital Pasteur
Nice, Alpes-Maritimes, 06001, France
Groupe Hospitalier Pellegrin
Bordeaux, Gironde, 33076, France
Multi-profile Clinic "New Hospitals"
Tbilisi, 0114, Georgia
Pineo Medical Ecosystem
Tbilisi, 0114, Georgia
Aversi Clinic - Central Branch
Tbilisi, 0160, Georgia
Simon Khechinashvili University Hospital
Tbilisi, 0179, Georgia
IRCCS Fondazione Casa Sollievo della Sofferenza SG Rotondo
San Giovanni Rotondo, Foggia, 71013, Italy
Fondazione Istituto San Raffaele - G. Giglio Di Cefalu
Cefalù, Palermo, 90015, Italy
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Naples, 80131, Italy
Azienda Ospedaliera Universitaria - Università degli Studi della Campania Luigi Vanvitelli
Naples, 80131, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, 80131, Italy
Istituto Neurologico Casimiro Mondino
Pavia, 27100, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, 00168, Italy
Azienda Ospedaliera - Universitaria Sant' Andrea
Rome, 00189, Italy
National Hospital Organization - Nagoya Medical Center
Nagoya, Aichi-ken, 460-0001, Japan
Sapporo Medical University Hospital
Sapporo, Hokkaido, 060-8543, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
Kobe University Hospital
Kobe, Hyōgo, 650-0017, Japan
St. Marianna University Hospital
Kawasaki, Kanagawa, 216-8511, Japan
Yokohama Medical Center
Yokohama, Kanagawa, 245-8575, Japan
NHO Sendai Medical Center
Sendai, Miyagi, 983-8520, Japan
National Hospital Organization Niigata National Hospital
Kashiwazaki-Shi, Niigata, 945-8585, Japan
Okinawa National Hospital
Ginowan-Shi, Okinawa, 901-2214, Japan
Nagoya City University Hospital
Suita-shi, Osaka, 564-0013, Japan
Seirei Hamamatsu General Hospital
Hamamatsu, Sizuoka [Shizuoka], 430-8558, Japan
Tokushima University Hospital
Tokushima, Tokusima [Tokushima], 770-8503, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, 160-0023, Japan
Kyushu University Hospital
Fukuoka, 812-8582, Japan
National Hospital Organization Utano National Hospital
Kyoto, 616-8255, Japan
Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD
Poznan, Greater Poland Voivodeship, 61-853, Poland
Medicover Integrated Clinical Services (MICS) - Centrum Medyczne Bydgoszcz
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-065, Poland
Neurocentrum Bydgoszcz
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Krakowska Akademia Neurologii Sp. z o.o.
Krakow, Lesser Poland Voivodeship, 31-505, Poland
Clinirem - Lublin
Lublin, Lublin Voivodeship, 20-064, Poland
Centrum Medyczne Hope Clinic
Lublin, Lubusz Voivodeship, 20-701, Poland
Twoja Przychodnia Nowosolskie Centrum Medyczne
Nowa Sól, Lubusz Voivodeship, 67-100, Poland
Centrum Medyczne Neuroprot
Warsaw, Masovian Voivodeship, 01-684, Poland
MTZ Powered by Pratia
Warsaw, Masovian Voivodeship, 02-172, Poland
Uniwersyteckie Centrum Kliniczne w Gdańsku
Gdansk, Pomeranian Voivodeship, 80-214, Poland
Neurologia Śląska Centrum Medyczne
Katowice, Silesian Voivodeship, 40-123, Poland
Hospital Universitari Mútua Terrassa
Terrassa, Barcelona, 08221, Spain
Hospital Universitario de Basurto
Bilbao, Biscay, 48013, Spain
Hospital General Universitario Dr. Balmis
Alicante, 03010, Spain
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
Hospital Universitari i Politècnic La Fe
Valencia, 46026, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2024
First Posted
June 13, 2024
Study Start
July 17, 2024
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
January 1, 2029
Last Updated
March 10, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share